288 related articles for article (PubMed ID: 10837181)
1. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
King I; Itterson M; Bermudes D
Methods Mol Biol; 2009; 542():649-59. PubMed ID: 19565926
[TBL] [Abstract][Full Text] [Related]
5. Complete genome sequence of Salmonella enterica serovar Typhimurium VNP20009, a strain engineered for tumor targeting.
Broadway KM; Modise T; Jensen RV; Scharf BE
J Biotechnol; 2014 Dec; 192 Pt A():177-8. PubMed ID: 25046822
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
7. Construction of VNP20009: a novel, genetically stable antibiotic-sensitive strain of tumor-targeting Salmonella for parenteral administration in humans.
Low KB; Ittensohn M; Luo X; Zheng LM; King I; Pawelek JM; Bermudes D
Methods Mol Med; 2004; 90():47-60. PubMed ID: 14657558
[No Abstract] [Full Text] [Related]
8. Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
Jia LJ; Wei DP; Sun QM; Huang Y; Wu Q; Hua ZC
Cancer Sci; 2007 Jul; 98(7):1107-12. PubMed ID: 17498202
[TBL] [Abstract][Full Text] [Related]
9. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium.
Mei S; Theys J; Landuyt W; Anne J; Lambin P
Anticancer Res; 2002; 22(6A):3261-6. PubMed ID: 12530073
[TBL] [Abstract][Full Text] [Related]
10. Oral delivery of tumor-targeting Salmonella exhibits promising therapeutic efficacy and low toxicity.
Chen G; Wei DP; Jia LJ; Tang B; Shu L; Zhang K; Xu Y; Gao J; Huang XF; Jiang WH; Hu QG; Huang Y; Wu Q; Sun ZH; Zhang JF; Hua ZC
Cancer Sci; 2009 Dec; 100(12):2437-43. PubMed ID: 19793349
[TBL] [Abstract][Full Text] [Related]
11. Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 Ligand expression plasmids in melanoma-bearing mouse.
Yoon WS; Choi WC; Sin JI; Park YK
Biotechnol Lett; 2007 Apr; 29(4):511-6. PubMed ID: 17235489
[TBL] [Abstract][Full Text] [Related]
12. Attenuated Salmonella VNP20009 mutant (ΔhtrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency.
Xu W; Zhou T; Zhou J; Qiang Z; Zhang J; Hua Z
Lett Appl Microbiol; 2018 Jul; 67(1):97-103. PubMed ID: 29698572
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF; Gill VJ; Hwu P; Marincola FM; Restifo NP; Schwartzentruber DJ; Sherry RM; Topalian SL; Yang JC; Stock F; Freezer LJ; Morton KE; Seipp C; Haworth L; Mavroukakis S; White D; MacDonald S; Mao J; Sznol M; Rosenberg SA
J Clin Oncol; 2002 Jan; 20(1):142-52. PubMed ID: 11773163
[TBL] [Abstract][Full Text] [Related]
14. NTP Technical Report on the metabolism, toxicity and predicted carcinogenicity of diazoaminobenzene (CAS No. 136-35-6).
Ress NB;
Toxic Rep Ser; 2002 Sep; (73):1-23, A1-C6. PubMed ID: 12370695
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice.
Zhao M; Yang M; Ma H; Li X; Tan X; Li S; Yang Z; Hoffman RM
Cancer Res; 2006 Aug; 66(15):7647-52. PubMed ID: 16885365
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Anticancer Activities and Biosafety Between
Liu X; Guo Y; Sun Y; Chen Y; Tan W; Min JJ; Zheng JH
Front Microbiol; 2022; 13():914575. PubMed ID: 35847095
[No Abstract] [Full Text] [Related]
17. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of a DNA vaccine delivered in attenuated Salmonella typhimurium against Toxoplasma gondii infection in mice.
Qu D; Wang S; Cai W; Du A
Vaccine; 2008 Aug; 26(35):4541-8. PubMed ID: 18590785
[TBL] [Abstract][Full Text] [Related]
19. [Construction of the non-resistant attenuated Salmonella typhimurium strain expressing Helicobacter pylori catalase].
Bai Y; Zhang YL; Wang JD; Zhang ZS; Zhou DY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Feb; 23(2):101-5. PubMed ID: 12581952
[TBL] [Abstract][Full Text] [Related]
20. Effect of Antibiotic Treatment on Attenuated
Ahmed SG; Brenner GJ
Anticancer Res; 2023 Jan; 43(1):1-6. PubMed ID: 36585175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
